Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNP-610 in Non-alcoholic Steatohepatitis (NASH)
NCT03468556Phase 2Not yet recruiting
- Sponsor
- Sinew Pharma
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Small Molecules, Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of SNP-610 in Nonalcoholic steatohepatitis (NASH), sponsored by Sinew Pharma. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
SNP-610
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03468556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468556.